Literature DB >> 7579487

Vasopressin gene related products are markers of human breast cancer.

W G North1, S Pai, A Friedmann, X Yu, M Fay, V Memoli.   

Abstract

Immunohistochemical analysis for products of vasopressin and oxytocin gene expression was performed on acetone-fixed tissues from 19 breast cancers representing a variety of tumor sub-types. Studies employed the avidin-biotin complex (ABC) immunohistochemical procedure and utilized rabbit polyclonal antibodies to arginine vasopressin (VP), provasopressin (ProVP), vasopressin-associated human glycopeptide (VAG), oxytocin (OT), oxytocin-associated human neurophysin (OT-HNP), and a mouse monoclonal antibody to vasopressin-associated human neurophysin (VP-HNP). Western Blot analysis was performed on protein extracts of fresh-frozen tissues from 12 additional breast tumors. While VP gene related proteins were not detected in normal breast tissue, immunohistochemistry revealed the presence of VP, ProVP, and VAG in all neoplastic cells for all of the tumor tissues examined. Vasopressin-associated human neurophysin was evident in only one of 19 acetone-fixed tumor preparations. However, Western blot analysis for all 12 fresh-frozen tumor samples showed the presence of two proteins, 42,000 and 20,000 daltons, that were immunoreactive with antibodies to VP, VP-HNP, and VAG. Oxytocin and OT-HNP, by immunohistochemistry, were found to be common to cells of normal breast tissues. For tumors, positive staining for OT was observed in 8 of 18 tumors, while OT-HNP was not detected in any of the tumors examined. These findings indicate that VP gene expression is a selective feature of all breast cancers, and that products of this expression might therefore be useful as markers for early detection of this disease and as possible targets for immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579487     DOI: 10.1007/BF00689714

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  Inhibition of erythrocyte pseudoperoxidase activity by treatment with hydrogen peroxide following methanol.

Authors:  J G Streefkerk
Journal:  J Histochem Cytochem       Date:  1972-10       Impact factor: 2.479

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Detection of breast cancer.

Authors:  P Strax
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

4.  R-verapamil decreases anti-estrogen resistance in a breast cancer model.

Authors:  J A Kellen; A Wong; E Georges; V Ling
Journal:  Anticancer Res       Date:  1991 Mar-Apr       Impact factor: 2.480

Review 5.  The development of biological therapies for breast cancer.

Authors:  M E Lippman
Journal:  Science       Date:  1993-01-29       Impact factor: 47.728

6.  Neurohypophysial-hormone-responsive cell line derived from a dimethylbenzanthracene-induced rat mammary tumour.

Authors:  M E Monaco; W R Kidwell; M E Lippman
Journal:  Biochem J       Date:  1980-05-15       Impact factor: 3.857

7.  Interaction of vasopressin and oxytocin with human breast carcinoma cells.

Authors:  A H Taylor; V T Ang; J S Jenkins; J J Silverlight; R C Coombes; Y A Luqmani
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

8.  Human neurophysins as potential tumor markers for small cell carcinoma of the lung: application of specific radioimmunoassays.

Authors:  W G North; L H Maurer; H Valtin; J F O'Donnell
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

9.  Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease.

Authors:  W G North
Journal:  J Clin Endocrinol Metab       Date:  1991-12       Impact factor: 5.958

10.  Isolation and partial characterization of two human neurophysins: their use in the development of specific radioimmunoassays.

Authors:  W G North; F T LaRochelle; J Melton; R C Mills
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

View more
  9 in total

1.  Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.

Authors:  Nicholas G Paciaroni; Verrill M Norwood; Ranjala Ratnayake; Hendrik Luesch; Robert W Huigens
Journal:  Bioorg Med Chem       Date:  2020-05-07       Impact factor: 3.641

2.  Breast cancer expresses functional NMDA receptors.

Authors:  William G North; Guohong Gao; Vincent A Memoli; Roy H Pang; Launa Lynch
Journal:  Breast Cancer Res Treat       Date:  2009-09-26       Impact factor: 4.872

3.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

4.  Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS).

Authors:  William G North; Wendy Wells; Michael J Fay; Rennie S Mathew; Edward M Donnelly; Vincent A Memoli
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  Detection of Provasopressin in Invasive and Non-invasive (DCIS) Human Breast Cancer Using a Monoclonal Antibody Directed Against the C-terminus (MAG1).

Authors:  Brendan P Keegan; Vincent A Memoli; Wendy A Wells; William G North
Journal:  Breast Cancer (Auckl)       Date:  2010-04-08

Review 6.  Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin.

Authors:  D F Alonso; G V Ripoll; J Garona; N B Iannucci; D E Gomez
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

7.  The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.

Authors:  Juan Garona; Marina Pifano; Ulises D Orlando; Maria B Pastrian; Nancy B Iannucci; Hugo H Ortega; Ernesto J Podesta; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Int J Oncol       Date:  2015-04-03       Impact factor: 5.650

8.  Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.

Authors:  Giselle V Ripoll; Juan Garona; Marina Pifano; Hernan G Farina; Daniel E Gomez; Daniel F Alonso
Journal:  Breast Cancer Res Treat       Date:  2013-11       Impact factor: 4.872

9.  A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Authors:  Ruth S Weinberg; Marcelo O Grecco; Gimena S Ferro; Debora J Seigelshifer; Nancy V Perroni; Francisco J Terrier; Analía Sánchez-Luceros; Esteban Maronna; Ricardo Sánchez-Marull; Isabel Frahm; Marcelo D Guthmann; Daniela Di Leo; Eduardo Spitzer; Graciela N Ciccia; Juan Garona; Marina Pifano; Ana V Torbidoni; Daniel E Gomez; Giselle V Ripoll; Roberto E Gomez; Ignacio A Demarco; Daniel F Alonso
Journal:  Springerplus       Date:  2015-08-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.